Jeffrey S. Hackman bought $105k of FENC
Chief Executive Officer at FENNEC PHARMACEUTICALS INC.. 15,000 shares at an average of $6.97, traded May 16, 2025, filed May 19, 2025.
Score components
- +25RoleCEO
- +10Trade size$105k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.7%, 3m +7.2%, 6m +14.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-013673, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | POpen-market purchase Common Shares | +1,035 | $6.75 | $6,986 | 1,035 | May 19, 2025 |
| May 19, 2025 | POpen-market purchase Common Shares | +13,965 | $6.99 | $98k | 15,000 | May 19, 2025 |
Related signals
Other insiders at FENNEC PHARMACEUTICALS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | FENNEC PHARMACEUTICALS INC. | Marco Maria Brughera director | $160k 15,545 shares | -100% | |
| 13Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov other | $121k 10,000 shares | -7% | |
| 61Notable | FENNEC PHARMACEUTICALS INC. | Pierre Sargis Sayad Chief Medical Officer | $146k 12,000 shares | -56% | |
| 35Weak | FENNEC PHARMACEUTICALS INC. | Robert Andrade CHIEF FINANCIAL OFFICER | $884k 75,000 shares | -26% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov other | $96k 10,000 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov other | $100k 9,599 shares | -6% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov director | $94k 9,747 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Chris A Rallis director | $59k 8,346 shares | -12% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov director | $70k 10,781 shares | -8% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov director | $69k 10,946 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.